GUILLERMO RODRIGUEZ

Dr. GUILLERMO RODRIGUEZ


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AGAntonio Gutierrez
Antonio Gutierrez
LBLeyre Bento
Leyre Bento
SNSilvana Novelli
Silvana Novelli
AMAlejandro Martín
Alejandro Martín
GGGonzalo Gutierrez
Gonzalo Gutierrez
O(On Behalf Of The Grupo Español de Trasplante de Progenitores Hematopoyéticos (Geth) And Grupo Español de Linfoma Y Trasplante Autólogo (Geltamo)
On Behalf Of The Grupo Español de Trasplante de Progenitores Hematopoyéticos (Geth) And Grupo Español de Linfoma Y Trasplante Autólogo (Geltamo)
Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. The primary endpoints were EFS, OS, and cumulative incidence (CI) of NRM, relapse, and GVHD. We included 135 patients, most (85%) receiving RIC. After a median follow-up of 68 months, 5-year EFS and OS were 47 and 50%, respectively. Overall and CR rates were 86 and 80%. The CI of relapse at 1 and 3 years were 7 and 12%. NRM at day 100 and 1 year were 17 and 32%. Previous ASCT and Grade 3–4 aGVHD were associated with a higher NRM. Grade 3–4 aGVHD, donor type (mismatch non-related), and the time-period 2006–2020 were independently related to worse EFS. Patients from 1995–2005 were younger, most from HLA-identical sibling donors, and were pretreated less. Our data confirmed that allo-SCT may be a curative option in R/R MCL with low a CI of relapse, although NRM is still high, being mainly secondary to aGVHD. The arrival of new, highly effective and low toxic immunotherapeutic or targeted therapies inevitably will relegate allo-SCT to those fit patients who fail these therapies, far away from the optimal timing of treatment.

24 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AGAlfonso Rodríguez Gil
Alfonso Rodríguez Gil
ECEstrella Carrillo-Cruz
Estrella Carrillo-Cruz
CMCristina Marrero-Cepeda
Cristina Marrero-Cepeda
GRGUILLERMO RODRIGUEZ
GUILLERMO RODRIGUEZ
JPJose A Perez-Simon
Jose A Perez-Simon
The different cell subsets of the immune system express the vitamin D receptor (VDR). Through the VDR, vitamin D exerts different functions that influence immune responses, as previously shown in different preclinical models. Based on this background, retrospective studies explored the impacts of vitamin D levels on the outcomes of patients undergoing allogeneic hematopoietic stem-cell transplantation, showing that vitamin D deficiency is related to an increased risk of complications, especially graft-versus-host disease. These results were confirmed in a prospective cohort trial, although further studies are required to confirm this data. In addition, the role of vitamin D on the treatment of hematologic malignancies was also explored. Considering this dual effect on both the immune systems and tumor cells of patients with hematologic malignancies, vitamin D might be useful in this setting to decrease both graft-versus-host disease and relapse rates.

3 March 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
AGAlfonso Rodríguez Gil
Alfonso Rodríguez Gil
ECEstrella Carrillo-Cruz
Estrella Carrillo-Cruz
CMCristina Marrero-Cepeda
Cristina Marrero-Cepeda
GRGUILLERMO RODRIGUEZ
GUILLERMO RODRIGUEZ
JPJose A Perez-Simon
Jose A Perez-Simon
The different cell subsets of the immune system express vitamin D receptor (VDR). Through VDR, vitamin D exerts different functions which influences on immune responses, as previously shown in different preclinical models. Based on this background, retrospective studies have explored the impact of vitamin D levels on the outcome of patients undergoing allogeneic hematopoietic stem cell transplantation, showing that vitamin D deficiency is related to an increased risk of complications, especially graft-versus-host disease. These results have been confirmed in a prospective cohorts trial, although further studies are required to confirm this data. In addition, the role of vitamin D on the treatment of hematologic malignancies has also been explored. Considering this dual effect both on the immune system as well as on tumor cells in patients with hematologic malignancies, vitamin D might be useful in this setting both to decrease graft-versus-host disease and relapse rates.